RecruitingNot ApplicableNCT05302583

Aromatherapy Inhaler Use for HSCT Distress

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress


Sponsor

Stanford University

Enrollment

50 participants

Start Date

Jun 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).


Eligibility

Min Age: 19 Years

Inclusion Criteria7

  • Autologous and Allogeneic patients admitted to E1 for planned HSCT
  • Patients with hematologic malignancies requiring HSCT
  • No allergies to lavender or peppermint essential oils
  • Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
  • Adult patient over 18 years of age
  • Able to speak, read, and comprehend English
  • Willing and capable of providing informed consent

Exclusion Criteria11

  • Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
  • Patients receiving a transplant for a germ cell tumor diagnosis
  • Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
  • Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
  • History of scleroderma
  • History of atrial fibrillation
  • Known history of G6PD deficiency
  • Allergic to lavender or peppermint essential oils
  • Pediatric patient 18 years of age or less
  • Unable to speak, read, and comprehend English
  • Unwilling or incapable of providing informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAromatherapy Inhaler

Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler


Locations(1)

Stanford University

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05302583


Related Trials